Evidence brief · printable

Epilepsy evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Epilepsy: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/epilepsy.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Lacosamide 6 trials
  • Brivaracetam 2.5 mg 2 trials
  • Levetiracetam 2 trials
  • Topiramate 2 trials
  • Air polishing with erythritol powder 1 trial
  • Almotriptan malate 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Transcranial brain stimulation (tDCS, TMS) 31 trials · 17 completed · 6 with results
  • Vagus and cranial nerve stimulation 32 trials · 10 completed · 6 with results
  • Care coordination, navigation and outreach 10 trials · 5 completed · 3 with results
  • Melatonin 3 trials · 2 completed · 2 with results
  • Education, coaching and self-management 26 trials · 14 completed · 1 with results
  • Peripheral electrical and electromagnetic stimulation 9 trials · 4 completed · 1 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • Omega-3 Fatty Acids
  • Cannabidiol (CBD)
  • Folic Acid (Vitamin B9)
  • Melatonin
  • Black Seed Oil

Biomarkers reported

Direction in patients compared with the stated comparison group, as reported in the cited study.

  • Ammonia higher · Vakrinou et al. 2022
  • Creatine Kinase higher · Paltrinieri et al. 2017
  • GFAP higher · Runtz et al. 2018
  • High-Mobility Group Box 1 (HMGB1) higher · Walker et al. 2022
  • Interleukin-6 higher · Tsuji et al. 2011
  • Lactate higher · Chatzikonstantinou et al. 2015

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical… NCT07600736
  • A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients… NCT07594158
  • A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of… NCT07723963
  • Bridging the Treatment Gap by Expanding Access to Care for People With Epilepsy in… NCT06623994
  • Spatial Scene Recognition Memory in Epilepsy Surgery NCT07580183
  • An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy NCT00859794

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Among 30 trials of cognitive training and education found, none measured inflammation and other biomarkers 54 trials of other approaches did
  • Among 10 trials of care delivery and health services found, none measured inflammation and other biomarkers 54 trials of other approaches did
  • Among 9 trials of other devices and digital tools found, none measured inflammation and other biomarkers 54 trials of other approaches did
  • Diet, fasting and nutrition: symptom severity and disease activity 26 trials, no results posted yet
  • Mind-body and psychological approaches: quality of life 14 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (349 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page · biomarker atlas. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.